Arcadia Biosciences Inc
$ 1.07
3.88%
05 Jun - close price
- Market Cap 2,200,900 USD
- Current Price $ 1.07
- High / Low $ 1.08 / 0.94
- Stock P/E N/A
- Book Value 1.40
- EPS -5.72
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -1.58 %
- 52 Week High 5.72
- 52 Week Low 0.80
About
Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.
Analyst Target Price
$12.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-26 | 2025-11-07 | 2025-08-14 | 2025-05-08 | 2025-03-20 | 2024-11-12 | 2024-08-13 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -2.1053 | -0.9759 | 0.62 | -3.26 | 1.9 | -2.99 | -0.87 | 0.78 | -1.78 | -2.52 | -1.44 | -2.65 |
| Estimated EPS | None | None | -0.94 | -1.22 | -0.98 | -0.89 | -0.81 | 1.55 | -2.21 | -2.58 | -3.19 | -4.8 |
| Surprise | 0 | 0 | 1.56 | -2.04 | 2.88 | -2.1 | -0.06 | -0.77 | 0.43 | 0.06 | 1.75 | 2.15 |
| Surprise Percentage | None% | None% | 165.9574% | -167.2131% | 293.8776% | -235.9551% | -7.4074% | -49.6774% | 19.457% | 2.3256% | 54.8589% | 44.7917% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RKDA
2026-05-20 14:09:59
Arcadia Biosciences Inc. (RKDA) stock has surged by 34.94% due to high volume and investor optimism, attracting short-term traders. Despite significant losses and negative returns, the company maintains a strong balance sheet with minimal debt and robust liquidity. Traders are capitalizing on its inherent volatility and discounted valuation (0.41x sales, 0.68x book value) as a short-term trading vehicle rather than a long-term investment.
2026-05-15 16:10:46
Armistice Capital, along with Steven Boyd, has filed a Schedule 13G reporting a beneficial ownership of 159,390 shares in Arcadia Biosciences, Inc. (RKDA), representing a 7.75% stake. The filing indicates shared voting and dispositive power over these shares, with Armistice Capital acting as the investment manager for Armistice Capital Master Fund Ltd., the direct holder. This passive investment disclosure highlights institutional ownership in Arcadia Biosciences.
2026-05-15 11:11:03
Arcadia Biosciences (RKDA) reported its first-quarter 2026 financial results, highlighting an 18% increase in Zola® coconut water volumes and record-low selling, general, and administrative expenses. Despite an overall revenue decrease, the company's CEO, T.J. Schaefer, expressed satisfaction with their performance and noted plans to launch a new product in the fall while continuing to evaluate strategic alternatives. The company reported a net loss of $4.4 million for the quarter, largely due to a warrant inducement offer transaction and other losses, compared to a net income in the prior year.
2026-05-15 09:10:46
Arcadia Biosciences (RKDA) announced its first quarter 2026 financial and business results, highlighting an 18% year-over-year increase in Zola® coconut water volumes and achieving the lowest SG&A expenses in its history. Despite a decrease in total reported revenues, the company is focused on growing its Zola brand and plans to launch a new product this fall while continuing to evaluate strategic alternatives. The net loss attributable to common stockholders was $4.4 million for the quarter, largely due to a warrant inducement offer transaction and other losses, compared to a net income in the prior year.
2026-05-14 23:39:19
This document is Arcadia Biosciences' 10-Q filing for the first quarter of 2026. A 10-Q is a comprehensive quarterly report submitted by public companies to the SEC, providing a detailed overview of their financial performance and condition. It includes unaudited financial statements and provides a continuing view of the company's financial position during the year.
2026-05-14 23:08:00
Arcadia Biosciences Inc. (RKDA) reported a first-quarter loss of $4.4 million, translating to a loss of $2.11 per share. The agricultural biotechnology trait company, based in Dallas, also announced revenues of $1.1 million for the same period. This financial summary was generated using data from Zacks Investment Research.
